3D Printing Therapeutics at Scale with Aprecia Pharmaceuticals

About this episode

This episode explores how 3D printing is transforming pharmaceutical manufacturing with insights from Aprecia Pharmaceuticals.

In this episode of Data in Biotech , Ross Katz sits down with Kyle Smith and Jacob Mayer from Aprecia Pharmaceuticals to explore how 3D printing is transforming pharmaceutical manufacturing. They dive into the unique binder jetting process, in-cavity printing, and how real-time data and automation are enabling agile, scalable, and precise drug production. Discover how Aprecia's approach is changing the game for clinical trials and personalized medicine. What you'll learn in this episode: >> How Aprecia developed the world’s first FDA-approved 3D printed drug >> Why binder jetting stands out among 3D printing methods in pharma >> How in-cavity 3D printing enables real-time tablet-level data collection >> The future of closed-loop control and digital twins in drug manufacturing >> Why 3D printing is key to agile, distributed, and personalized pharma production Meet our guests: Kyle Smith is President and COO of Aprecia Pharmaceuticals, leading strategic growth and innovation in GMP-regulated pharma manufacturing. With 12+ years at Aprecia, he brings deep expertise in engineering, operations, and technology transfer. Jacob Maye r is Director of…

People in this episode

Host: Ross Katz

Guests: Kyle Smith, Jacob Mayer

Topics covered

• 3D printing
• pharmaceutical manufacturing
• binder jetting
• real-time data
• personalized medicine
• clinical trials

Keywords

• 3D printing
• pharmaceuticals
• binder jetting
• drug production
• clinical trials
• personalized medicine
• automation

Mentioned in this episode

Organizations: Aprecia Pharmaceuticals, CorrDyn

Products: FDA-approved 3D printed drug

More episodes of Data in Biotech

• From Tissue to Mechanism to Decision: Building AI for Computational Oncology · June 2, 2026 · 47 min
• Cavities in the Data: Building FDA-Cleared AI for Dental Imaging with Overjet · May 13, 2026 · 59 min
• Data as a Moat: Why Biotech's Most Valuable Asset is Buried in a Hard Drive · April 30, 2026 · 43 min
• Markus Gershater on Why Experimental Design in Biotech is Broken and How to Fix It · April 15, 2026 · 41 min
• Data Science and Diagnostic Models - the What, Why and How with Michelle Wiest · April 15, 2026 · 44 min
• The Patient is Not a Document: Foundation Models for Biomedical AI with Standard BioModel · April 15, 2026 · 50 min